11/14/12 (W) 12:00 - 1:30 pm
Rochester BioVenture Center, 77 Ridgeland Road, Rochester, NY
The road to approval of a new drug involves advancing through several phases, and pre-clinical testing is one of the first major hurdles in determining whether a lead compound will proceed further on the path to reaching the market. Care in planning and executing the pre-clinical trials can help prevent rejection of viable leads as well as establish a firm foundation for those candidates that can proceed to the Investigational New Drug Application stage.
Are you looking for a research lab to collaborate on pre-clinical work? Calvert Labs will present a discussion of their laboratory services for pre-clinical testing of new drug and vaccine candidates, along with a presentation on the expanding pharmaceutical development at Bausch + Lomb.
Charles Spainhour, V.M.D., Ph.D.
President and Chief Science Officer, Calvert Labs
Dr. Spainhour has over 30 years experience in the pharmaceutical industry he has written numerous papers, books and is an expert on regulatory compliance. He also has worked at a number of companies from Pharmakon Research, Chrysalis International, Phoenix International Life Sciences and Smith Kline & French Laboratories (now GlaxoSmithKline Corporation). He is a Diplomate American Board of Forensic Science, Diplomate American Board of Toxicology and Diplomate American Board of Forensic Medicine.
Mary Richardson, PhD, DABT
Executive Director of Preclinical Develpoment, Bausch + Lomb
Ms. Richardson currently serves in the research and development of ocular pharmaceutical products at Bausch + Lomb. She works in Toxicology, Drug Metabolism and Pharmacokinetics, and prior to her role as executive director, she was a director of nonclinical safety. Mary was with Proctor & Gamble before joining B+L.
FREE EVENT—REGISTRATION REQUIRED
SPACE IS LIMITED--PLEASE REGISTER EARLY!
A light lunch will be available
Registration closes November 13, 2012 at 5:00 pm!
Return to Top